The new deal extends and expands the companies’ previous three-year agreement from 2009.
BioSeek will expand the use of its BioMAP platform to evaluate Merck small molecule compounds and proteins across multiple therapeutic areas.
Asterand chairman and interim chief executive officer Jack Davis said the studies carried out by BioSeek for Merck over the past three years have demonstrated that BioMAP Platform can be used to advance promising molecules through preclinical evaluation.